Derwich-Rudowicz Aleksandra, Żbikowska Aleksandra, Ruchała Marek, Andrusiewicz Mirosław, Moskal Jakub, Sawicka-Gutaj Nadia
Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznań, Poland.
Doctoral School, Poznan University of Medical Sciences, Bukowska 70, 60-812 Poznań, Poland.
Int J Mol Sci. 2025 May 6;26(9):4408. doi: 10.3390/ijms26094408.
The study aimed to analyze hsa-miR-16-5p, hsa-miR-143-3p, hsa-miR-423-5p, hsa-miR-137-3p, hsa-miR-489-5p, hsa-miR-520-3p, hsa-miR-486-5p, and hsa-miR-200a-3p expression in the serum of patients with invasive non-functioning pituitary adenomas (NFPAs) and prolactinomas, as candidates for non-invasive biomarkers. The study included 62 patients with NFPAs and 18 with macroprolactinoma who qualified for transsphenoidal surgical resection. MicroRNAs were isolated from serum samples. The expression levels of hsa-miR-16-5p, hsa-miR-143-3p, hsa-miR-423-5p, hsa-miR-137-3p, hsa-miR-489-5p, hsa-miR-520-3p, hsa-miR-486-5p, and hsa-miR-200a-3p were determined using TaqMan MicroRNA assays. The statistical analyses were performed with MedCalc. The total concentration of microRNA was significantly lower in NFPAs than in the CG ( = 0.0419). ROC curve analysis showed that the cutoff point of miRNA lower than 10.73 predicted the PA (sensitivity = 70.0%; specificity = 57.7%; AUC = 0.629; = 0.052). No correlation between selected miRNAs and tumor type was found: hsa-miR-143-3p ( = 0.4610), hsa-miR-16-5p ( = 0.8767), and hsa-miR-423-5p ( = 0.1459). miRNA expression also did not correlate with invasiveness (cavernous or sphenoid sinus invasion, optic chiasm compression). Although the total expression of microRNA was significantly lower in NFPAs, hsa-miR-16-5p, hsa-miR-143-3p, and hsa-miR-423-5p are not useful as non-invasive biomarkers in patients with invasive non-functioning pituitary adenomas and prolactinomas.
该研究旨在分析侵袭性无功能垂体腺瘤（NFPAs）和催乳素瘤患者血清中hsa-miR-16-5p、hsa-miR-143-3p、hsa-miR-423-5p、hsa-miR-137-3p、hsa-miR-489-5p、hsa-miR-520-3p、hsa-miR-486-5p和hsa-miR-200a-3p的表达情况，将其作为非侵入性生物标志物的候选指标。该研究纳入了62例符合经蝶窦手术切除条件的NFPAs患者和18例大催乳素瘤患者。从血清样本中分离出微小RNA。使用TaqMan微小RNA检测法测定hsa-miR-16-5p、hsa-miR-143-3p、hsa-miR-423-5p、hsa-miR-137-3p、hsa-miR-489-5p、hsa-miR-520-3p、hsa-miR-486-5p和hsa-miR-200a-3p的表达水平。采用MedCalc进行统计分析。NFPAs患者中微小RNA的总浓度显著低于对照组（P = 0.0419）。受试者工作特征（ROC）曲线分析表明，miRNA低于10.73的截断点可预测垂体腺瘤（敏感性 = 70.0%；特异性 = 57.7%；曲线下面积[AUC] = 0.629；P = 0.052）。未发现所选miRNA与肿瘤类型之间存在相关性：hsa-miR-143-3p（P = 0.4610）、hsa-miR-16-5p（P = 0.8767）和hsa-miR-423-5p（P = 0.1459）。miRNA表达也与侵袭性（海绵窦或蝶窦侵袭、视交叉受压）无关。尽管NFPAs患者中微小RNA的总表达显著较低，但hsa-miR-16-5p、hsa-miR-143-3p和hsa-miR-423-5p在侵袭性无功能垂体腺瘤和催乳素瘤患者中作为非侵入性生物标志物并无用处。
